Rep. Gilbert Ray Cisneros, Jr. Buys Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Vaxcyte, Inc. (NASDAQ:PCVX). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Vaxcyte stock on May 13th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.

Vaxcyte Price Performance

Vaxcyte stock traded down $1.46 during mid-day trading on Wednesday, hitting $45.42. The company’s stock had a trading volume of 1,029,561 shares, compared to its average volume of 1,420,229. The firm’s 50 day moving average is $54.72 and its 200 day moving average is $52.70. The company has a market cap of $6.56 billion, a PE ratio of -6.60 and a beta of 1.24. Vaxcyte, Inc. has a 52-week low of $29.08 and a 52-week high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the previous year, the firm earned ($1.04) earnings per share. As a group, analysts forecast that Vaxcyte, Inc. will post -7.56 EPS for the current year.

Insider Buying and Selling

In related news, CAO Elvia Cowan sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $60.00, for a total value of $180,000.00. Following the transaction, the chief accounting officer directly owned 28,975 shares of the company’s stock, valued at approximately $1,738,500. This trade represents a 9.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $49.52, for a total value of $111,420.00. Following the completion of the transaction, the chief operating officer directly owned 158,494 shares in the company, valued at $7,848,622.88. The trade was a 1.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 9,392 shares of company stock worth $524,426 over the last three months. 3.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PCVX. Royal Bank of Canada raised its stake in shares of Vaxcyte by 115.2% in the 1st quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock valued at $1,113,000 after acquiring an additional 15,774 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Vaxcyte in the 1st quarter valued at approximately $219,000. Caxton Associates LLP bought a new position in shares of Vaxcyte in the 1st quarter valued at approximately $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Vaxcyte by 8.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock valued at $19,409,000 after acquiring an additional 41,034 shares in the last quarter. Finally, Cetera Investment Advisers raised its stake in shares of Vaxcyte by 13.8% in the 2nd quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock valued at $250,000 after acquiring an additional 932 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group reaffirmed a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. BTIG Research raised their price target on Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Vaxcyte currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.